Skip to content
Not yet recruitingPhase 4

Dexmedetomidine-Esketamine Combination on Depression and Anxiety After Laparoscopic Ureteral Reconstruction

NCT07753772 · Peking University First Hospital

Closed to entry
Status
Not accepting participants
Phase 4
Phase
658
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

Anxiety and depressive symptoms are prevalent in patients undergoing surgical repair for ureteral stricture, driven by chronic pain, renal function concerns, and surgical uncertainty. Dexmedetomidine has anxiolytic and antidepressant effects but may increase bradycardia and hypotension; esketamine provides rapid antidepressant efficacy but may cause psychiatric side effects. Preliminary studies showed that combined use of low-dose dexmedetomidine and esketamine reduced the prevalence of postoperative depressive symptoms without increasing adverse events. This study is designed to test the hypothesis that perioperative use of low-dose dexmedetomidine-esketamine combination may relieve postoperative depressive symptoms and anxiety in patients undergoing laparoscopic ureteral reconstruction.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Prevalence of depressive symptoms on postoperative day 7

    Measured over On postoperative day 7.

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: 1. Aged ≥ 18 years; 2. Diagnosed with ureteral stricture and scheduled for elective laparoscopic ureteral reconstruction under general anesthesia; 3. Requiring patient-controlled intravenous analgesia after surgery. Exclusion Criteria: 1. Preoperative inability to communicate due to coma, delirium, severe dementia, or language barrier; 2. History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis; 3. Presence of preexisting left ventricular ejection fraction (LVEF) \< 30%, sick sinus syndrome, severe sinus bradycardia (heart rate \< 50 beats/min), or atrioventricular block above grade II without pacemaker implanted; 4. Uncontrolled hyperthyroidism or history of pheochromocytoma; 5. Severe hepatic insufficiency (Child-Pugh Class C), severe renal insufficiency (required preoperative dialysis), or American Society of Anesthesiologists (ASA) physical status classification ≥ IV; 6. Allergy to dexmedetomidine and/or esketamine; 7. Other conditions deemed unsuitable for study participation by the investigators.

Where

1 study site

FacilityCityRegionCountry
Peking University First HospitalBeijingBeijing MunicipalityChina

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07753772 on ClinicalTrials.gov →

Last updated in the registry 2026-08-14. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits